About Us
Our comprehensive DTPC offers a detailed analysis and treatment plan for patients with sleep disorders. Utilizing state-of-the-art 3D CBCT imaging technology, we provide accurate measurements and expert interpretations to assist in the diagnosis and management of sleep-related conditions.
With over 25 years of experience, we are dedicated to providing the highest possible standard of diagnostic and treatment planning services.
Meet our CEO and Founder
Professor G. Dave Singh is a US citizen who was born, educated and trained in England, UK. He holds three doctorates, including Doctor of Dental Medicine; a Ph.D. in craniofacial cleft palate development; and a third Doctorate in Orthodontics. Dr Singh was awarded a postgraduate grant (University of Oxford, UK) and was later appointed to the Board of Examiners, Royal College of Surgeons of England. Supported by Harvard University, the University of Michigan, and the University of Hawaii, he was invited to relocate to the Center for Craniofacial Disorders, University of Puerto Rico, USA where he led a NIH-funded program of clinical craniofacial research. Currently, he is an honorary diplomate of the American Sleep and Breathing Academy, a Member of the World Sleep Society, a Member of the American Academy of Sleep Medicine, an Academic Fellow of the World Federation of Orthodontists, and a Fellow of the International Association for Orthodontics, where he was awarded prizes in 2005, 2013 and 2014.
He has published over 200 articles in the peer-reviewed medical, dental and orthodontic literature, and has published 9 books/chapters. During 2008-2016, Dr Singh was the Founder and CEO of his start-up company, which was successfully listed on NASDAQ after its IPO in 2020. During that time, he had approximately 12 US, Canadian and international patents issued. In 2019, Dr. Singh was the recipient of the US Invisible Disabilities Association award. In 2020, Dr Singh was given a lifetime achievement award for his work on obstructive sleep apnea. Dr Singh is the inventor of the DNA appliance, which was the first palatal expander to be FDA approved in 2023 for the treatment of mild-moderate and severe obstructive sleep apnea in adults. In 2024, the DNA appliance became the first palatal expander to be FDA approved for the treatment of obstructive sleep apnea in children, and later that year Dr Singh became a Fellow of the prestigious Pierre Fauchard Academy. Dr Singh is a former Adjunct Professor in Sleep Medicine at Stanford University, USA.